RPRX - Company ID 0001802768
The table below shows Royalty Pharma plc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $452.00M | $2.00M | $52.00M | $177.11M | $200.08M | $26.29M |
| SG&A |
Royalty Pharma plc reported annual revenue of $2.38B for fiscal year 2025. That is up 5.1% from $2.26B in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $1.79B (FY 2018) to $2.38B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $573.48M |
| $236.67M |
| $249.75M |
| $227.30M |
| $182.83M |
| $181.72M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M |
| EPS (diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 |